Resources
About Us
Real-world Evidence Analytics Market by Application [Market Access & Reimbursement, Drug Development & Approval (Oncology, Neurology, Cardiovascular), Post Market Surveillance, Medical Device Development], End User (Pharma, Payer, Provider) - Global Forecast to 2029
Report ID: MRHC - 104620 Pages: 180 Jun-2022 Formats*: PDF Category: Healthcare Delivery: 24 to 72 Hours Download Free Sample ReportThe Real-world Evidence Analytics Market is expected to grow at a CAGR of 15.1% during the forecast period 2022–2029 to reach $2.93 billion by 2029. The report analyses various RWE analytics solutions offered by key companies for different applications, including market access & reimbursement/coverage decisions, drug development & approvals, post-market surveillance, medical device development & approvals, and clinical & regulatory decision-making. These solutions are used by various end users such as pharmaceutical, biotechnology, and medical device companies, healthcare payers, and healthcare providers. Rapidly-growing big data in healthcare, a shift from volume to value-based care, and a rising focus on personalized healthcare are the primary drivers for the growth of the RWE analytics market.
Data management & integration enhancements help improve the speed & quality of drug discovery and clinical trial processes. Artificial intelligence (AI) is employed in real-world data (RWD) to enhance data anomaly detection, standardization, and quality check at the pre-processing stage. AI is expected to offer pharma & biotech companies the ability to increase meaningful RWE output, decrease time to insights, and make the most of the available vast data sources. RWE technology platforms delivering smart data processing, analysis, and outcomes offer an unparalleled opportunity to capitalize on these computing advancements. When used as a part of a comprehensive RWE strategy, AI innovations can enhance drug development, improve patient treatment & access, and drive valuable new business opportunities.
Click here to: Get Sample Pages of this Report
Market Access & Reimbursement/Coverage Decisions to Dominate the Market
The market access & reimbursement/coverage decisions segment is estimated to account for the largest share of the RWE analytics market in 2022. The large market share of this segment is mainly attributed to the increasing demand for RWD and RWE to accelerate market access & reimbursement/coverage decisions, increasing investments by biopharmaceutical companies in R&D, and the growing inclination of regulatory bodies toward the use of RWE.
Pharmaceutical, Biotechnology, and Medical Device Companies Segment to Register the Largest Share in the RWE Analytics Market by 2029
The pharmaceutical, biotechnology, and medical device companies segment is estimated to account for the largest share of the RWE analytics market in 2022. The large market share of this segment is mainly attributed to the increasing importance of RWE analytics in drug development & approvals, and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.
North America to Dominate the Regional Market
North America is estimated to command the largest share of the global RWE analytics market in 2022, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The rising burden of chronic diseases in the geriatric population, a shift towards value-based care, growing personalized healthcare, availability of electronic datasets, a well-developed healthcare industry, and rising big data in the healthcare sector are some of the major factors expected to drive the growth of this segment.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past four years . The key players profiled in the global RWE analytics market report include Clinigen Group plc (U.K.), ICON plc (Ireland), IQVIA Holdings Inc. (U.S.), Oracle Corporation (U.S.), Parexel International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).
Scope of the Report
Real-world Evidence Analytics Market, by Application
Real-world Evidence Analytics Market, by End User
Real-world Evidence Analytics Market, by Geography
Key questions answered in the report:
The global RWE analytics market covers the market sizes & forecasts of various RWE analytics solutions offered by the key market players to support pharmaceutical, biotechnology, and medical device companies, healthcare payers, healthcare providers, and other end users in making key decisions related to market access & reimbursement/coverage decisions, drug development & approvals, post-market surveillance, medical device development & approvals. The RWE analytics market studied in this report involves the value analysis of various segments and sub-segments of RWE analytics solution providers at regional and country levels.
The global RWE analytics market is projected to reach $2.93 billion by 2029, at a CAGR of 15.1% during the forecast period.
The drug development & approvals segment is estimated to register the highest CAGR during the forecast period due to increasing demand for real-world data and real-world evidence analytics to accelerate drug discovery and development, increasing investments by biopharmaceutical companies in R&D, and the growing inclination of regulatory bodies towards the use of real-world evidence.
Growing incidence of chronic diseases, delay in drug development and the subsequent increase in development costs, rapidly-growing big data in the healthcare sector, a shift from volume to value-based care, and rising focus on personalized healthcare have been considered to positively impact the RWE analytics market. Furthermore, significant opportunities for existing market players and new entrants by emerging markets, rising focus on end-to-end RWE services, and rising adoption of wearable devices in RWE are boosting the growth of this market.
Key companies operating in the global RWE analytics market are Clinigen Group plc (U.K.), ICON plc (Ireland), IQVIA Holdings Inc. (U.S.), Oracle Corporation (U.S.), Parexel International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).
Emerging economies such as Japan and China in Asia are projected to offer significant growth opportunities for the companies in this market. Growing demand for data defining the value and effectiveness of medicines by payers, growing demand for real-world studies in drug R&D, and increasing government interest in using real-world studies for regulatory decision-making are expected to offer significant growth opportunities in this region.
Published Date: Aug-2024
Published Date: Dec-2022
Published Date: Oct-2022
Published Date: Dec-2022
Please enter corporate email id here & we’ll send you a free sample.
Subscribe to get the latest industry updates